Seagen
-
Seagen and Nurix Join Forces to Develop a New Class of Cancer Medicines
Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.
-
Pfizer’s Seagen Acquisition Brings It Full Circle in a Hot Area of Cancer Drug R&D
Pfizer is no stranger to antibody drug conjugate cancer therapies, but it hasn’t been commercially successful with them. The pharma giant’s agreement to acquire Seagen for $43 billion will thrust it to the forefront of the ADC drug class, which has become a hot space for research and regulatory activity in recent years.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Seagen broadens its scope beyond ADC cancer drugs with deal for preclinical asset
Seagen’s cancer drug research and collaborations have focused on the development of antibody drug conjugates. By licensing rights to a preclinical Lava Therapeutics asset, Seagen gets a shot to develop a different kind of antibody therapy that could compete against approved products from Johnson & Johnson and Takeda Pharmaceutical.
-
Sanofi and Seagen team up to grow a new crop of ADC cancer drugs
Antibody drug conjugates have made scientific and regulatory progress in recent years. Sanofi is partnering with ADC specialist Seagen in a multi-drug alliance that keeps the pharmaceutical giant in the mix of this growing field of cancer therapies.
-
Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer
The Seagen and Genmab antibody drug conjugate (ADC), named Tivdak, is approved to treat cases of cervical cancer that have returned or spread following treatment with chemotherapy. Tivdak is Seagen’s third ADC; for Genmab, the drug will become its first commercialized product.
-
Seattle Genetics rebrands as Seagen as it expands business globally
The company has received FDA approvals for two cancer drugs in less than 12 months and announced partnerships with Merck last month for a Phase II antibody-drug conjugate and a marketed drug.
Promoted
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
